Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Lokavant provides clinical trial intelligence
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Kivo’s expanded platform brings compliant collaboration and intelligent process automation to emerging Regulatory, Clinical and Quality teams
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Subscribe To Our Newsletter & Stay Updated
